| 1.83 0.15 (8.93%) | 06-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.25 |
1-year : | 2.63 |
| Resists | First : | 1.92 |
Second : | 2.25 |
| Pivot price | 1.68 |
|||
| Supports | First : | 1.68 |
Second : | 1.52 |
| MAs | MA(5) : | 1.7 |
MA(20) : | 1.69 |
| MA(100) : | 1.77 |
MA(250) : | 1.71 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 58.5 |
D(3) : | 43.5 |
| RSI | RSI(14): 61.2 |
|||
| 52-week | High : | 2.25 | Low : | 1.33 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IKT ] has closed Bollinger Bands are 47.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.83 - 1.84 | 1.84 - 1.85 |
| Low: | 1.69 - 1.7 | 1.7 - 1.71 |
| Close: | 1.82 - 1.83 | 1.83 - 1.84 |
Inhibikase Therapeutics, Inc. operates as a pharmaceutical firm in the clinical development stage, concentrating its efforts on pioneering treatments for Parkinson's Disease (PD) and a range of associated neurological conditions that impact both the brain and other parts of the body. The company's investigational pipeline includes IkT-148009, a small molecule designed to inhibit Abelson tyrosine kinase. This candidate aims to address not only Parkinson's disease itself but also early-stage gastrointestinal complications often experienced by PD patients, such as swallowing difficulties (dysphagia), neurologically-induced constipation, and multiple system atrophy. Additionally, Inhibikase is advancing IkT-001Pro through preclinical development. This prodrug, derived from the anti-cancer agent Imatinib, is intended to lessen typical gastrointestinal side effects while providing treatment for blood and stomach cancers. Beyond these primary compounds, the company is also pursuing various research programs focused on other neurological disorders. Inhibikase actively collaborates on research and development initiatives with several prominent academic institutions, including The Johns Hopkins University, Arizona State University, Michigan State University, and Louisiana State University. Established in 2008, Inhibikase Therapeutics, Inc. maintains its corporate headquarters in Atlanta, Georgia.
Thu, 18 Jun 2026
Inhibikase Therapeutics Inc (IKT) Institutional Confidence - TradingKey
Thu, 18 Jun 2026
Inhibikase Therapeutics Inc (IKT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Fri, 15 May 2026
Perceptive Advisors/Perceptive Life Sciences disclose 8.9% holding in IKT (IKT) - Stock Titan
Wed, 08 Apr 2026
H.C. Wainwright reiterates Inhibikase stock rating on trial progress - Investing.com
Fri, 03 Apr 2026
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 132 (M) |
| Shares Float | 87 (M) |
| Held by Insiders | 6.4 (%) |
| Held by Institutions | 93.3 (%) |
| Shares Short | 18,510 (K) |
| Shares Short P.Month | 17,980 (K) |
| EPS | -0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.98 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.7 % |
| Return on Equity (ttm) | -40.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -36 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -4.16 |
| PEG Ratio | 0 |
| Price to Book value | 1.86 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.77 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|